LONDON— 7 January 2011—Cell Medica, a leading cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, is pleased to announce that Gregg Sando, CEO of Cell Medica will provide a company update and highlight its plans for its innovative cellular immunotherapy development programs at the Biotech Showcase 2011 Conference. The presentation will take place on Wednesday, January 12 at 10am in the Mission II room, 4th Floor, Parc 55 Wyndham San Francisco, Union Square, 55 Cyril Magnin Street, San Francisco, 94102.
About Cell Medica
Cell Medica is a leading cellular therapeutics company engaged in developing, manufacturing and marketing of cellular immunotherapy treatment strategies for infectious disease and cancer. The Company’s lead clinical application, Cytovir CMV, is for the treatment of cytomegalovirus infections in patients following allogeneic haematopoietic stem cell (bone marrow) transplant. The Company is currently sponsoring a confirmatory (Phase III style) clinical trial for Cytovir CMV across 15 bone marrow transplant centers in the UK. The development of cancer immunotherapy applications represents a natural progression of the Company’s core expertise in using antigen-specific T cells immunotherapy to treat disease. Cell Medica has a built a strong network of research partnerships with clinicians, scientists and universities including the Royal Free Hospital, University College London, Imperial College London, and recently further strengthened its relationship with the Center for Cell and Gene Therapy, Baylor College of Medicine, in an exclusive license agreement for cell based treatments associated with the oncogenic Epstein Barr virus.
For further information visit www.cellmedica.co.uk or contact:
About the Biotech Showcase™ (Innovation – Opportunity – Collaboration):
Now in its third year, Biotech Showcase™ will feature corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all showcase participants can schedule one-on-one meetings through the organizer’s online system, partneringONE™. Public and private investors are always invited to attend the showcase on a complimentary basis. The Biotech Showcase™ was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life sciences industry. Visit our website for more information: http://www.ebdgroup.com/bts/index.php.
Gregg Sando, CEO
Cell Medica Limited
+44 (0)20 7554 4070
Mary-Jane Elliott/ Nick Francis/ Amber Bielecka
+44 (0)20 7920 2352